CL2020003423A1 - Activadores de la respuesta a proteínas desplegadas - Google Patents
Activadores de la respuesta a proteínas desplegadasInfo
- Publication number
- CL2020003423A1 CL2020003423A1 CL2020003423A CL2020003423A CL2020003423A1 CL 2020003423 A1 CL2020003423 A1 CL 2020003423A1 CL 2020003423 A CL2020003423 A CL 2020003423A CL 2020003423 A CL2020003423 A CL 2020003423A CL 2020003423 A1 CL2020003423 A1 CL 2020003423A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer cells
- kill
- therapy
- activators
- response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Conjunto de biomoduladores ER de moléculas pequeñas que destruyen las células cancerosas de mama, ovario y endometrio ER positivas resistentes a la terapia. Estas pequeñas moléculas tienen un mayor potencial terapéutico debido a la mayor capacidad para destruir las células de cáncer de mama resistentes a la terapia en comparación con BHPI y otras terapias convencionales (terapias endocrinas, tamoxifeno y fulvestrant/ICI). Los nuevos compuestos no solo inhiben la proliferación de las células cancerosas, sino que también realmente las destruye, lo que evita la reactivación de los tumores años después.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862693641P | 2018-07-03 | 2018-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020003423A1 true CL2020003423A1 (es) | 2021-05-14 |
Family
ID=69059783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020003423A CL2020003423A1 (es) | 2018-07-03 | 2020-12-29 | Activadores de la respuesta a proteínas desplegadas |
Country Status (22)
Country | Link |
---|---|
US (3) | US20210276951A1 (es) |
EP (1) | EP3817741A4 (es) |
JP (1) | JP2021529757A (es) |
KR (1) | KR20210027382A (es) |
CN (1) | CN112423743A (es) |
AU (1) | AU2019299221A1 (es) |
BR (1) | BR112020025591A2 (es) |
CA (1) | CA3103958A1 (es) |
CL (1) | CL2020003423A1 (es) |
CO (1) | CO2020016690A2 (es) |
CR (1) | CR20210060A (es) |
DO (1) | DOP2020000256A (es) |
EA (1) | EA202190146A1 (es) |
EC (1) | ECSP20084330A (es) |
IL (1) | IL279429A (es) |
JO (1) | JOP20200344A1 (es) |
MA (1) | MA53105A (es) |
MX (1) | MX2021000043A (es) |
PE (1) | PE20210662A1 (es) |
PH (1) | PH12020552223A1 (es) |
SG (1) | SG11202012902WA (es) |
WO (1) | WO2020009958A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20210060A (es) | 2018-07-03 | 2021-04-08 | Univ Illinois | Activadores de la respuesta a proteínas desplegadas |
WO2021222738A1 (en) * | 2020-05-01 | 2021-11-04 | The Board Of Trustees Of The University Of Illinois | Compounds for estrogen receptor positive cancers |
WO2022020605A1 (en) * | 2020-07-23 | 2022-01-27 | The Board Of Trustees Of The University Of Illinois | Treatment of metastasized estrogen receptor positive breast cancer |
WO2022032146A1 (en) * | 2020-08-07 | 2022-02-10 | Systems Oncology, Llc | Methods for inhibiting growth of era positive cancers |
WO2022087234A1 (en) * | 2020-10-23 | 2022-04-28 | The Board Of Trustees Of The University Of Illinois | Anticancer compounds selective for er-positive cancers |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1487792A1 (en) | 2002-03-15 | 2004-12-22 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
JP4989976B2 (ja) * | 2004-02-13 | 2012-08-01 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 翻訳開始阻害剤としての3−3−二置換オキシインドール |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
KR20060130781A (ko) * | 2004-04-08 | 2006-12-19 | 토포타겟 에이/에스 | 다이페닐 인돌-2-온 화합물 및 암 치료에 있어서의 그의용도 |
JP2009510066A (ja) | 2005-09-29 | 2009-03-12 | ワイス | 血管運動症状(vms)の治療のためのモノアミン再取り込みのモジュレータである1−(1h−インドール−1−イル)−3−(メチルアミノ)−1−フェニルプロパン−2−オール誘導体および関連の化合物 |
PE20080655A1 (es) | 2006-08-24 | 2008-07-14 | Wyeth Corp | Proceso para preparar derivados de indolinona fenilaminopropanol |
US20100029646A1 (en) | 2006-12-11 | 2010-02-04 | Topo Target A/S | Prodrugs of diphenyl ox-indol-2-one compounds |
WO2008129075A1 (en) * | 2007-04-24 | 2008-10-30 | Topotarget A/S | Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds |
US7858666B2 (en) | 2007-06-08 | 2010-12-28 | Mannkind Corporation | IRE-1α inhibitors |
WO2010109008A1 (en) | 2009-03-26 | 2010-09-30 | Topotarget A/S | Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones |
WO2014047437A1 (en) | 2012-09-20 | 2014-03-27 | President And Fellows Of Harvard College | 3-3-di-substituted-oxindoles as inhibitors of translation initiation |
US9316631B1 (en) | 2012-10-19 | 2016-04-19 | Whitehead Institute For Biomedical Research | ER-stress inducing compounds and methods of use thereof |
EP2945646A4 (en) * | 2013-01-18 | 2016-09-21 | David J Shapiro | ESTROGEN RECEPTOR INHIBITORS |
JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | eIF2α経路の調節因子 |
LT3004090T (lt) | 2013-05-28 | 2018-01-10 | Astrazeneca Ab | Cheminiai junginiai |
CR20210060A (es) | 2018-07-03 | 2021-04-08 | Univ Illinois | Activadores de la respuesta a proteínas desplegadas |
-
2019
- 2019-07-01 CR CR20210060A patent/CR20210060A/es unknown
- 2019-07-01 US US17/254,771 patent/US20210276951A1/en active Pending
- 2019-07-01 MA MA053105A patent/MA53105A/fr unknown
- 2019-07-01 CA CA3103958A patent/CA3103958A1/en not_active Abandoned
- 2019-07-01 KR KR1020217001833A patent/KR20210027382A/ko unknown
- 2019-07-01 SG SG11202012902WA patent/SG11202012902WA/en unknown
- 2019-07-01 MX MX2021000043A patent/MX2021000043A/es unknown
- 2019-07-01 BR BR112020025591-2A patent/BR112020025591A2/pt not_active IP Right Cessation
- 2019-07-01 JP JP2020573046A patent/JP2021529757A/ja active Pending
- 2019-07-01 JO JOP/2020/0344A patent/JOP20200344A1/ar unknown
- 2019-07-01 EP EP19831532.7A patent/EP3817741A4/en not_active Withdrawn
- 2019-07-01 PE PE2020002206A patent/PE20210662A1/es unknown
- 2019-07-01 EA EA202190146A patent/EA202190146A1/ru unknown
- 2019-07-01 AU AU2019299221A patent/AU2019299221A1/en not_active Abandoned
- 2019-07-01 WO PCT/US2019/040058 patent/WO2020009958A1/en active Application Filing
- 2019-07-01 CN CN201980045131.2A patent/CN112423743A/zh active Pending
-
2020
- 2020-02-26 US US16/801,839 patent/US11046647B2/en active Active
- 2020-12-14 IL IL279429A patent/IL279429A/en unknown
- 2020-12-19 PH PH12020552223A patent/PH12020552223A1/en unknown
- 2020-12-29 EC ECSENADI202084330A patent/ECSP20084330A/es unknown
- 2020-12-29 CL CL2020003423A patent/CL2020003423A1/es unknown
- 2020-12-29 DO DO2020000256A patent/DOP2020000256A/es unknown
- 2020-12-30 CO CONC2020/0016690A patent/CO2020016690A2/es unknown
-
2021
- 2021-05-13 US US17/319,447 patent/US11584718B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20210027382A (ko) | 2021-03-10 |
SG11202012902WA (en) | 2021-01-28 |
MA53105A (fr) | 2021-05-12 |
ECSP20084330A (es) | 2021-01-29 |
CN112423743A (zh) | 2021-02-26 |
MX2021000043A (es) | 2021-03-25 |
PH12020552223A1 (en) | 2021-06-28 |
DOP2020000256A (es) | 2021-03-15 |
BR112020025591A2 (pt) | 2021-03-23 |
US20210276951A1 (en) | 2021-09-09 |
US20200190029A1 (en) | 2020-06-18 |
PE20210662A1 (es) | 2021-03-31 |
CA3103958A1 (en) | 2020-01-09 |
EA202190146A1 (ru) | 2021-04-27 |
EP3817741A4 (en) | 2022-07-06 |
CO2020016690A2 (es) | 2021-01-18 |
JP2021529757A (ja) | 2021-11-04 |
IL279429A (en) | 2021-01-31 |
JOP20200344A1 (ar) | 2020-12-31 |
WO2020009958A1 (en) | 2020-01-09 |
US20210340100A1 (en) | 2021-11-04 |
US11046647B2 (en) | 2021-06-29 |
EP3817741A1 (en) | 2021-05-12 |
AU2019299221A1 (en) | 2021-02-04 |
CR20210060A (es) | 2021-04-08 |
US11584718B2 (en) | 2023-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003423A1 (es) | Activadores de la respuesta a proteínas desplegadas | |
AR110728A1 (es) | Terapia combinada para el tratamiento del cáncer | |
CO2020009091A2 (es) | Exosomas para inmunooncología y terapia antiinflamatoria | |
CL2018002683A1 (es) | Antígeno prostático específico de membrana dirigido a agentes de alta afinidad para la endo radio terapia del cáncer de próstata | |
UY38236A (es) | COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3 | |
CO2021008224A2 (es) | Inhibidores de kif18a | |
CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
EA201990187A1 (ru) | Антипролиферационные средства на основе пиримидина | |
CO2020013252A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
BR112015026095A8 (pt) | método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor | |
EA201891526A2 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
EA201792520A2 (ru) | Способы и композиции для определения резистентности к терапии, направленной на андрогенный рецептор | |
CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
EA201790082A1 (ru) | Ингибиторы лизин-специфической демитилазы-1 | |
CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
CO2021004789A2 (es) | Piridazinonas y sus métodos de uso | |
CL2021001593A1 (es) | Tubulisinas y conjugados de proteína-tubulisina | |
CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
CO2020008561A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
BR112018015749A2 (pt) | ativador de fármaco contendo fósforo, suspensão de um ativador de fármaco contendo fósforo, e, sistema e método para tratamento de uma doença. | |
EA201991330A1 (ru) | Способы лечения рака с помощью антител к tim-3 |